NVISION Eye Centers Sign National Account Agreement for Imprimis Pharmaceuticals' Ophthalmic Compounded Formulations (2022)

One of the largest LASIK and cataract surgery providers in the U.S. adopts Dropless Therapy™ injectables and LessDrops™ topical drops at its 24 U.S. centers in the Western United States

NVISION Eye Center patients may be able to reduce or eliminate the number of eye drops needed following cataract surgery, LASIK, and other ocular procedures

SAN DIEGOand ALISO VIEJO, Calif., Nov. 24, 2015 /PRNewswire/ --Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary compounded drug therapies, and NVISION Eye Centers, Inc., one of the largest U.S. providers of LASIK and cataract surgery, today announced they have entered into an agreement to provide NVISION Eye Center patients with Dropless Therapy™ following cataract surgery and LessDrops™ topical drops following cataract, LASIK and other ocular procedures.

"As the innovative national leader in ophthalmology at the forefront of patient care, and the Eye Doctors' #1 Choice®, we are pleased to implement Dropless Therapy™ and LessDrops™ combination drop formulations at our 24 centers in California, Nevada, Oregon and Arizona," stated James Pereyra, President of NVISION Eye Centers. "Our dedicated world-class surgeons and staff utilize the latest state-of-the-art technologies and techniques and offering Dropless Cataract Surgery™ and LessDrops options for our patients is in line with our primary focus of providing the best possible patient experience and outcomes."

Mark L. Baum, CEO of Imprimis, stated, "We welcome NVISION Eye Centers as a major national account customer. Our proprietary injectable and topical drop formulations have broad applications in ophthalmic surgery and we believe they provide a variety of benefits, including economic, to patients and physicians. It is apparent that patients undergoing various types of ocular surgeries present different needs that include both injectable and topical administrations. Our goal is to service all our ophthalmic customers with offerings that address their preferred method of therapy for their patients."

Mr. Baum added, "In addition to our proprietary Dropless Therapy™ and combination topical formulations, we are also providing NVISION Eye Centers with an array of additional ophthalmic preparations they need on a regular basis to serve their patients. We have the unique opportunity to supply our customers with offerings from our compounding pharmacies that provide the convenience and cost-savings associated with one-stop shopping and top-quality client care."

About Imprimis' Dropless Therapy™ and Combination Topical Formulations

Imprimis' proprietary ophthalmic compounded formulations have been optimized for both injectable and topical applications compatible with the eye. The proprietary drug formulations allow for the increased solubility of a variety of active pharmaceutical ingredients, creating small, uniform particle sizes which enable them to be combined for administration as either an injectable at the time of surgery or used as a topical eye drop post-operatively. Tri-Moxi (triamcinolone acetonide and moxifloxacin hydrochloride) and Tri-Moxi-Vanc (with added vancomycin) are available in single, injectable intraocular doses administered during ocular surgery, where as a result of surgery, there is inflammation and a chance for post-operative infection. Over 400 ophthalmologists are now prescribing Imprimis' proprietary Dropless Therapy™ compounded formulations. Since its launch in April 2014, Dropless Therapy™ formulations have been administered in over 100,000 eye surgeries, primarily cataract surgeries. Ophthalmologists have reported that Dropless Therapy™ formulations may substantially reduce or eliminate the need for costly eye drops following ocular surgeries, thereby simplifying post-operative patient care and helping to provide safeguards against bacterial infection and inflammation. More information is available at www.GoDropless.com.

Imprimis' portfolio of combination drop therapy topical formulations may require up to 50% fewer drops to be administered by patients and may provide significant cost savings of up to 75% compared to current traditional post-surgery eye drop treatments. The LessDrops™ educational campaign aims to improve patient compliance and alleviate patient confusion associated with complex eye drop regimens. For more information, please visit www.LessDrops.com.

About NVISION Eye Centers

NVISION Eye Centers is one of the largest providers of LASIK and cataract surgery in the U.S., with 24 centers in California, Nevada, Oregon and Arizona. An innovative leader in ophthalmology, NVISION is dedicated to providing the best patient experience through the use of the latest technology and treatment by the most talented and experienced surgeons in the industry. NVISION was founded in 2010 by Tom Tooma, M.D., one of the earliest pioneers of LASIK who has performed more than 100,000 procedures throughout his esteemed career. With more than 2,000 eye doctors referring their patients and trusting their own eyes to NVISION surgeons, NVISION Eye Centers is the Eye Doctors' #1 Choice®. For more information, visitwww.NVISIONCenters.comor call (877) 455-9942.

About Imprimis Pharmaceuticals

San Diego-based Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) is a national leader in the development, production and dispensing of novel compounded pharmaceuticals. The company's business primarily consists of four therapeutic segments including ophthalmology, urology, sinus and integrative medicine. Imprimis dispenses compounded pharmaceuticals in all 50 states from four facilities located in California, Texas, New Jersey and Pennsylvania. For more information about Imprimis, please visit the corporate website at www.ImprimisPharma.com.

All Imprimis compounded formulations may only be prescribed pursuant to a physician prescription for an individually identified patient consistent with federal and state laws governing compounded drug formulations.


This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward-looking statements." Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include risks and uncertainties related to Imprimis' ability to make commercially available its compounded formulations and technologies in a timely manner, at price points that are attractive to physicians and patients or at all; physician interest in prescribing and patient interest in using its formulations; risks related to its compounding pharmacy operations; its ability to enter into strategic alliances, including arrangements with pharmacies, physicians and healthcare organizations for the development and distribution of its formulations; its ability to obtain intellectual property protection for its assets; its ability to accurately estimate its expenses and cash burn, and raise additional funds when necessary; risks related to research and development activities; the projected size of the potential market for its technologies and formulations; unexpected new data, safety and technical issues; regulatory and market developments impacting compounding pharmacies, outsourcing facilities and the pharmaceutical industry; competition; and market conditions. These and additional risks and uncertainties are more fully described in Imprimis' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Such documents may be read free of charge on the SEC's web site at www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by law, Imprimis undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

Imprimis Pharmaceuticals Contacts

Investor Contact
Bonnie Ortega

Media Contact
Deb Holliday

NVISION Eye Centers Contact
Dimas Garcia
949.274.4652 x11024

Logo- http://photos.prnewswire.com/prnh/20150108/167712LOGO

SOURCE Imprimis Pharmaceuticals, Inc.; NVISION Eye Centers, Inc.

Related Links


Top Articles

Latest Posts

Article information

Author: Arline Emard IV

Last Updated: 12/20/2022

Views: 6620

Rating: 4.1 / 5 (72 voted)

Reviews: 95% of readers found this page helpful

Author information

Name: Arline Emard IV

Birthday: 1996-07-10

Address: 8912 Hintz Shore, West Louie, AZ 69363-0747

Phone: +13454700762376

Job: Administration Technician

Hobby: Paintball, Horseback riding, Cycling, Running, Macrame, Playing musical instruments, Soapmaking

Introduction: My name is Arline Emard IV, I am a cheerful, gorgeous, colorful, joyous, excited, super, inquisitive person who loves writing and wants to share my knowledge and understanding with you.